Sign in
Active, not recruitingPhase 3

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Key facts

Who runs it
Eli Lilly and Company
Where
Argentina, Austria, Belgium, Brazil, Czechia, France, India, Israel, Italy, Japan, Mexico, Poland, Spain, Türkiye, and United Kingdom59 sites in 15 countriesChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
58 people, planned
Started
12 Feb 2020
Ended
Oct 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Baricitinib
  • Tocilizumab
Record updated
11 August 2026

Who can take part

Age
1 year to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years
  • Participants must have at least 2 active joints at screening and baseline
  • Cohort 1 (IL-6 inhibitor therapy naive): Participants who are at least 1 year and less than 18 years of age, except in countries that restrict use of tocilizumab in participants less than 2 years of age
  • Cohort 2 (open-label baricitinib): Participants who are at least 1 year and less than 18 years of age

Who cannot take part

  • Participants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis
  • Participants must not have a current or recent (<4 weeks prior to baseline) clinically serious infection
  • Participants must not have a history or presence of any autoimmune inflammatory condition other than JIA
  • Participants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study
  • Participants must not have biologic features of Macrophage Activation Syndrome (MAS) over the past 12 weeks
  • Participants must not have a positive test for hepatitis B virus
  • Participants must not have evidence of active tuberculosis (TB) or untreated latent TB
  • Participants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis
  • Participants must not have persistent oligoarticular arthritis as defined by the ILAR criteria

Where is this trial?

It has sites in 15 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.

The 3 groups in the trial

  • Cohort 1 BaricitinibTreatment being tested

    Baricitinib given orally.

    Treatment: Baricitinib

  • Cohort 1 TocilizumabExisting treatment, for comparison

    Tocilizumab given Subcutaneously (SC).

    Treatment: Tocilizumab

  • Cohort 2 BaricitinibTreatment being tested

    Baricitinib given orally.

    Treatment: Baricitinib

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Record updated
11 August 2026